Tuning immune suppression in systemic autoimmunity with self-derived peptides

Inflammation and Allergy - Drug Targets

Volumn 7, Issue 4, 2008, Pages 253-259

  Singh, Ram Pyare ^a   Hahn, Bevra H ^a   La Cava, Antonio ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Autoimmunity; CD8+ T cells; Lupus; Regulatory T cells; Self derived peptides; TGF signaling; Tolerance

Indexed keywords

ALTERED PROTEIN LIGAND; AMYLOID BETA PROTEIN; ANTIGEN; COMPLEMENTARY DETEMING REGION 1; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EDRATIDE; GAMMA INTERFERON; IMMUNOLOGIC AGENT; INTERLEUKIN 2 RECEPTOR ALPHA; MULTIPLE ANTIGENIC PROTEIN; NUCLEOSOMAL HISTONE PROTEIN; NUCLEOSOMAL PROTEIN; PEPTIDE NUCLEIC ACID; PLACEBO; PROTEIN CONSENSUS; SELF ANTIGEN DERIVED PEPTIDE; SMD PROTEIN; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; CD28 ANTIGEN; IMMUNOSUPPRESSIVE AGENT; PEPTIDE;

ADOPTIVE TRANSFER; ALZHEIMER DISEASE; ANTIBODY PRODUCTION; ANTIGEN EXPRESSION; AUTOIMMUNITY; CD4+ CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; CYTOKINE RELEASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; GENE FUNCTION; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE COUNT; NONHUMAN; PHARMACOLOGICAL BLOCKING; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; TARGET CELL; TREATMENT RESPONSE; ANIMAL; AUTOIMMUNE DISEASE; CD4+ T LYMPHOCYTE; DRUG EFFECT; IMMUNOLOGY; PHYSIOLOGY;

ANIMALS; ANTIGENS, CD28; AUTOIMMUNE DISEASES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PEPTIDES; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA;

EID: 58249084120     PISSN: 18715281     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152808786848423     Document Type: Review

References (76)

1. Crispin, J.C.; Alcocer-Varela, J.; de Pablo, P.; Martinez, A.; Richaud-Patin, Y.; Alarcon-Segovia, D. Immunoregulatory defects in patients with systemic lupus erythematosus in clinical remission. Lupus, 2003, 12, 386-93.
2. Crispin, J.C.; Martinez, A.; Alcocer-Varela, J. Quantification of regulatory T cells in patients with systemic lupus erythematosus. J. Autoimmun., 2003, 21, 273-6.
3. Liu, M.F.; Wang, C.R.; Fung, L.L.; Wu, C.R. Decreased CD4+CD25+ T cells in peripheral blood of patients with systemic lupus erythematosus. Scand. J. Immunol., 2004, 59, 198-202.
4. Miyara, M.; Amoura, Z.; Parizot, C.; Badoual, C.; Dorgham, K.; Trad, S.; Nochy, D.; Debre, P.; Piette, J.C.; Gorochov, G. Global natural regulatory T cell depletion in active systemic lupus erythematosus. J. Immunol., 2005, 175, 8392-400.
5. Valencia, X.; Yarboro, C.; Illei, G.; Lipsky, P.E. Deficient CD4+CD25high T regulatory cell function in patients with active systemic lupus erythematosus. J. Immunol., 2007, 178, 2579-88.
6. Scalapino, K.J.; Tang, Q.; Bluestone, J.A.; Bonyhadi, M.L.; Daikh, D.I. Suppression of disease in New Zealand Black/New Zealand White lupus-prone mice by adoptive transfer of ex vivo expanded regulatory T cells. J. Immunol., 2006, 177, 1451-9.
7. Horwitz, D.A.; Gray, J.D.; Zheng, S.G. The potential of human regulatory T cells generated ex vivo as a treatment for lupus and other chronic inflammatory diseases. Arthritis Res., 2002, 4, 241-6.
8. La Cava, A.; Ebling, F.M.; Hahn, B.H. Ig-reactive CD4+CD25+ T cells from tolerized (New Zealand Black x New Zealand White)F1 mice suppress in vitro production of antibodies to DNA. J. Immunol., 2004, 173, 3542-8.
9. Horwitz, D.A.; Zheng, S.G.; Gray, J.D.; Wang, J.H.; Ohtsuka, K.; Yamagiwa, S. Regulatory T cells generated ex vivo as an approach for the therapy of autoimmune disease. Semin. Immunol., 2004, 16, 135-43.
10. Vargas-Rojas, M.I.; Crispin, J.C.; Richaud-Patin, Y.; Alcocer-Varela, J. Quantitative and qualitative normal regulatory T cells are not capable of inducing suppression in SLE patients due to T-cell resistance. Lupus, 2008, 17, 289-94.
11. Zhang, B.; Zhang, X.; Tang, F.L.; Zhu, L.P.; Liu, Y.; Lipsky, P.E. Clinical significance of increased CD4+CD25-Foxp3+ T cells in patients with new-onset systemic lupus erythematosus. Ann. Rheum. Dis., 2008, 67, 1037-40.
12. Venigalla, R.K.; Tretter, T.; Krienke, S.; Max, R.; Eckstein, V.; Blank, N.; Fiehn, C.; Ho, A.D.; Lorenz, H.M. Reduced CD4+,CD25- T cell sensitivity to the suppressive function of CD4+,CD25high,CD127 -/low regulatory T cells in patients with active systemic lupus erythematosus. Arthritis Rheum., 2008, 58, 2120-30.
13. Kaliyaperumal, A.; Michaels, M.A.; Datta, S.K. Antigen-specific therapy of murine lupus nephritis using nucleosomal peptides: tolerance spreading impairs pathogenic function of autoimmune T and B cells. J. Immunol., 1999, 162, 5775-83.
14. Riemekasten, G.; Langnickel, D.; Enghard, P.; Undeutsch, R.; Humrich, J.; Ebling, F.M.; Hocher, B.; Humaljoki, T.; Neumayer, H.; Burmester, G.R.; Hahn, B.H.; Radbruch, A.; Hiepe, F. Intravenous injection of a D1 protein of the Smith proteins postpones murine lupus and induces type 1 regulatory T cells. J. Immunol., 2004, 173, 5835-42.
15. Singh, R.R.; Ebling, F.M.; Sercarz, E.E.; Hahn, B.H. Immune tolerance to autoantibody-derived peptides delays development of autoimmunity in murine lupus. J. Clin. Invest., 1995, 96, 2990-6.
16. Singh, R.R.; Hahn, B.H.; Tsao, B.P.; Ebling, F.M. Evidence for multiple mechanisms of polyclonal T cell activation in murine lupus. J. Clin. Invest., 1998, 102, 1841-9.
17. Fan, G.C.; Singh, R.R. Vaccination with minigenes encoding V(H)- derived major histocompatibility complex class I-binding epitopes activates cytotoxic T cells that ablate autoantibody-producing B cells and inhibit lupus. J. Exp. Med., 2002, 196, 731-41.
18. Snyder, C.M.; Aviszus, K.; Heiser, R.A.; Tonkin, D.R.; Guth, A.M.; Wysocki, L.J. Activation and tolerance in CD4(+) T cells reactive to an immunoglobulin variable region. J. Exp. Med., 2004, 200, 1-11.
19. Eilat, E.; Dayan, M.; Zinger, H.; Mozes, E. The mechanism by which a peptide based on complementarity-determining region-1 of a pathogenic anti-DNA auto-Ab ameliorates experimental systemic lupus erythematosus. Proc. Natl. Acad. Sci. USA, 2001, 98, 1148-53.
20. Sharabi, A.; Haviv, A.; Zinger, H.; Dayan, M.; Mozes, E. Amelioration of murine lupus by a peptide, based on the complementarity determining region-1 of an autoantibody as compared to dexamethasone: different effects on cytokines and apoptosis. Clin. Immunol., 2006, 119, 146-55.
21. Sharabi, A.; Azulai, H.; Sthoeger, Z.M.; Mozes, E. Clinical amelioration of murine lupus by a peptide based on the complementarity determining region-1 of an autoantibody and by cyclophosphamide: similarities and differences in the mechanisms of action. Immunology, 2007, 121, 248-57.
22. Hahn, B.H.; Singh, R.P.; La Cava, A.; Ebling, F.M. Tolerogenic treatment of lupus mice with consensus peptide induces Foxp3-expressing, apoptosis-resistant, TGFbeta-secreting CD8+ T cell suppressors. J. Immunol., 2005, 175, 7728-37.
23. Singh, R.P.; La Cava, A.; Wong, M.; Ebling, F.; Hahn, B.H. CD8+ T cell-mediated suppression of autoimmunity in a murine lupus model of peptide-induced immune tolerance depends on Foxp3 expression. J. Immunol., 2007, 178, 7649-57.
24. Singh, R.P.; La Cava, A.; Hahn, B.H. pConsensus peptide induces tolerogenic CD8+ T cells in lupus-prone (NZB x NZW)F1 mice by differentially regulating Foxp3 and PD1 molecules. J. Immunol., 2008, 180, 2069-80.
25. Hahn, B.H. Lessons in lupus: the mighty mouse. Lupus, 2001, 10, 589-93.
26. Sakaguchi, S.; Sakaguchi, N.; Asano, M.; Itoh, M.; Toda, M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol., 1995, 155, 1151-64.
27. Sakaguchi, S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell, 2000, 101, 455-8.
28. Shevach, E.M. Regulatory T cells in autoimmmunity*. Annu. Rev. Immunol., 2000, 18, 423-49.
29. Shevach, E.M.; McHugh, R.S.; Piccirillo, C.A.; Thornton, A.M. Control of T-cell activation by CD4+ CD25+ suppressor T cells. Immunol. Rev., 2001, 182, 58-67.
30. Filaci, G.; Bacilieri, S.; Fravega, M.; Monetti, M.; Contini, P.; Ghio, M.; Setti, M.; Puppo, F.; Indiveri, F. Impairment of CD8+ T suppressor cell function in patients with active systemic lupus erythematosus. J. Immunol., 2001, 166, 6452-7.
31. Karpouzas, G.A.; La Cava, A.; Ebling, F.M.; Singh, R.R.; Hahn, B.H. Differences between CD8+ T cells in lupus-prone (NZB x NZW) F1 mice and healthy (BALB/c x NZW) F1 mice may influence autoimmunity in the lupus model. Eur. J. Immunol., 2004, 34, 2489-99.
32. Hahn, B.H.; Singh, R.R.; Wong, W.K.; Tsao, B.P.; Bulpitt, K.; Ebling, F.M. Treatment with a consensus peptide based on amino acid sequences in autoantibodies prevents T cell activation by autoantigens and delays disease onset in murine lupus. Arthritis Rheum., 2001, 44, 432-41.
33. Singh, R.R.; Ebling, F.M.; Albuquerque, D.A.; Saxena, V.; Kumar, V.; Giannini, E.H.; Marion, T.N.; Finkelman, F.D.; Hahn, B.H. Induction of autoantibody production is limited in nonautoimmune mice. J. Immunol., 2002, 169, 587-94.
34. Kang, H.K.; Michaels, M.A.; Berner, B.R.; Datta, S.K. Very low-dose tolerance with nucleosomal peptides controls lupus and induces potent regulatory T cell subsets. J. Immunol., 2005, 174, 3247-55.
35. Kang, H.K.; Liu, M.; Datta, S.K. Low-dose peptide tolerance therapy of lupus generates plasmacytoid dendritic cells that cause expansion of autoantigen-specific regulatory T cells and contraction of inflammatory th17 cells. J. Immunol., 2007, 178, 7849-58.
36. Rapoport, M.J.; Sharabi, A.; Aharoni, D.; Bloch, O.; Zinger, H.; Dayan, M.; Mozes, E. Amelioration of SLE-like manifestations in (NZBxNZW)F1 mice following treatment with a peptide based on the complementarity determining region 1 of an autoantibody is associated with a down-regulation of apoptosis and of the proapoptotic factor JNK kinase. Clin. Immunol., 2005, 117, 262-70.
37. Sela, U.; Mauermann, N.; Hershkoviz, R.; Zinger, H.; Dayan, M.; Cahalon, L.; Liu, J.P.; Mozes, E.; Lider, O. The inhibition of autoreactive T cell functions by a peptide based on the CDR1 of an anti-DNA autoantibody is via TGF-beta-mediated suppression of LFA-1 and CD44 expression and function. J. Immunol., 2005, 175, 7255-63.
38. Lemere, C.A.; Maron, R.; Selkoe, D.J.; Weiner, H.L. Nasal vaccination with beta-amyloid peptide for the treatment of Alzheimer's disease. DNA Cell Biol., 2001, 20, 705-11.
39. Weiner, H.L.; Friedman, A.; Miller, A.; Khoury, S.J.; al-Sabbagh, A.; Santos, L.; Sayegh, M.; Nussenblatt, R.B.; Trentham, D.E.; Hafler, D.A. Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. Annu. Rev. Immunol., 1994, 12, 809-37.
40. Faria, A.M.; Weiner, H.L. Oral tolerance and TGF-beta-producing cells. Inflamm. Allergy Drug Targets, 2006, 5, 179-90.
41. Hahn, B.H.: Anderson, M.: Lee, E.: La Cava, A. Anti-DNA Ig peptides promotes regulatory T cell activity in SLE patients. Arthritis Rheumatism, 2008, In press.
42. Fontenot, J.D.; Rasmussen, J.P.; Williams, L.M.; Dooley, J.L.; Farr, A.G.; Rudensky, A. Y. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity, 2005, 22, 329-41.
43. Nakamura, K.; Kitani, A.; Strober, W. Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J. Exp. Med., 2001, 194, 629-44.
44. Kumar, V.; Sercarz, E. An integrative model of regulation centered on recognition of TCR peptide/MHC complexes. Immunol. Rev., 2001, 182, 113-21.
45. Ben-David, H.; Sharabi, A.; Dayan, M.; Sela, M.; Mozes, E. The role of CD8+CD28 regulatory cells in suppressing myasthenia gravis-associated responses by a dual altered peptide ligand. Proc. Natl. Acad. Sci. USA, 2007, 104, 17459-64.
46. Zheng, S.G.; Wang, J.H.; Koss, M.N.; Quismorio, F.Jr.; Gray, J.D.; Horwitz, D.A. CD4+ and CD8+ regulatory T cells generated ex vivo with IL-2 and TGF-beta suppress a stimulatory graft-versus-host disease with a lupus-like syndrome. J. Immunol., 2004, 172, 1531-9.
47. Filaci, G.; Fravega, M.; Negrini, S.; Procopio, F.; Fenoglio, D.; Rizzi, M.; Brenci, S.; Contini, P.; Olive, D.; Ghio, M.; Setti, M.; Accolla, R.S.; Puppo, F.; Indiveri, F. Nonantigen specific CD8+ T suppressor lymphocytes originate from CD8+CD28- T cells and inhibit both T-cell proliferation and CTL function. Hum. Immunol., 2004, 65, 142-56.
48. Filaci, G.; Fravega, M.; Fenoglio, D.; Rizzi, M.; Negrini, S.; Viggiani, R.; Indiveri, F. Non-antigen specific CD8+ T suppressor lymphocytes. Clin. Exp. Med., 2004, 4, 86-92.
49. Horwitz, D.A.; Zheng, S.G.; Gray, J.D. The role of the combination of IL-2 and TGF-beta or IL-10 in the generation and function of CD4+ CD25+ and CD8+ regulatory T cell subsets. J. Leukoc. Biol., 2003, 74, 471-8.
50. Sharabi, A.; Luger, D.; Ben-David, H.; Dayan, M.; Zinger, H.; Mozes, E. The role of apoptosis in the ameliorating effects of a CDR1-based peptide on lupus manifestations in a mouse model. J. Immunol., 2007, 179, 4979-87.
51. Najafian, N.; Chitnis, T.; Salama, A.D.; Zhu, B.; Benou, C.; Yuan, X.; Clarkson, M.R.; Sayegh, M.H.; Khoury, S.J. Regulatory functions of CD8+CD28- T cells in an autoimmune disease model. J. Clin. Invest., 2003, 112, 1037-48.
52. Colovai, A.I.; Mirza, M.; Vlad, G.; Wang, S.; Ho, E.; Cortesini, R.; Suciu-Foca, N. Regulatory CD8+CD28- T cells in heart transplant recipients. Hum. Immunol., 2003, 64, 31-7.
53. Cosmi, L.; Liotta, F.; Lazzeri, E.; Francalanci, M.; Angeli, R.; Mazzinghi, B.; Santarlasci, V.; Manetti, R.; Vanini, V.; Romagnani, P.; Maggi, E.; Romagnani, S.; Annunziato, F. Human CD8+CD25+ thymocytes share phenotypic and functional features with CD4+CD25+ regulatory thymocytes. Blood, 2003, 102, 4107-14.
54. Shi, Y.; Massague, J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell, 2003, 113, 685-700.
55. Li, M.O.; Wan, Y.Y.; Sanjabi, S.; Robertson, A.K.; Flavell, R.A. Transforming growth factor-beta regulation of immune responses. Annu. Rev. Immunol., 2006, 24, 99-146.
56. Rubtsov, Y.P.; Rudensky, A.Y. TGFbeta signalling in control of Tcell-mediated self-reactivity. Nat. Rev. Immunol., 2007, 7, 443-53.
57. Derynck, R.; Zhang, Y.E. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature, 2003, 425, 577-84.
58. Park, I.K.; Letterio, J.J.; Gorham, J.D. TGF-beta 1 inhibition of IFN-gamma-induced signaling and Th1 gene expression in CD4+ T cells is Smad3 independent but MAP kinase dependent. Mol. Immunol., 2007, 44, 3283-90.
59. Yu, L.; Hebert, M.C.; Zhang, Y.E. TGF-beta receptor-activated p38 MAP kinase mediates Smad-independent TGF-beta responses. EMBO J., 2002, 21, 3749-59.
60. Itoh, S.; Thorikay, M.; Kowanetz, M.; Moustakas, A.; Itoh, F.; Heldin, C.H.; ten Dijke, P. Elucidation of Smad requirement in transforming growth factor-beta type I receptor-induced responses. J. Biol. Chem., 2003, 278, 3751-61.
61. Chen, C.H.; Seguin-Devaux, C.; Burke, N.A.; Oriss, T.B.; Watkins, S.C.; Clipstone, N.; Ray, A. Transforming growth factor beta blocks Tec kinase phosphorylation, Ca2+ influx, and NFATc translocation causing inhibition of T cell differentiation. J. Exp. Med., 2003, 197, 1689-99.
62. Fukuda, M.; Longnecker, R. Latent membrane protein 2A inhibits transforming growth factor-beta 1-induced apoptosis through the phosphatidylinositol 3-kinase/Akt pathway. J. Virol., 2004, 78, 1697-705.
63. Wohlfert, E.A.; Gorelik, L.; Mittler, R.; Flavell, R.A.; Clark, R.B. Cutting edge: deficiency in the E3 ubiquitin ligase Cbl-b results in a multifunctional defect in T cell TGF-beta sensitivity in vitro and in vivo. J. Immunol., 2006, 176, 1316-20.
64. Zheng, S.G.; Wang, J.; Wang, P.; Gray, J.D.; Horwitz, D.A. IL-2 is essential for TGF-beta to convert naive CD4+CD25- cells to CD25+Foxp3+ regulatory T cells and for expansion of these cells. J. Immunol., 2007, 178, 2018-27.
65. Davidson, T.S.; DiPaolo, R.J.; Andersson, J.; Shevach, E.M. Cutting Edge: IL-2 is essential for TGF-beta-mediated induction of Foxp3+ T regulatory cells. J. Immunol., 2007, 178, 4022-6.
66. Sloan-Lancaster, J.; Allen, P.M. Altered peptide ligand-induced partial T cell activation: molecular mechanisms and role in T cell biology. Annu. Rev. Immunol., 1996, 14, 1-27.
67. Boots, A.M.; Hubers, H.; Kouwijzer, M.; den Hoed-van Zandbrink, L.; Westrek-Esselink, B.M.; van Doorn, C.; Stenger, R.; Bos, E.S.; van Lierop, M.J.; Verheijden, G.F.; Timmers, C.M.; van Staveren, C.J. Identification of an altered peptide ligand based on the endogenously presented, rheumatoid arthritis-associated, human cartilage glycoprotein-39(263-275) epitope: an MHC anchor variant peptide for immune modulation. Arthritis Res. Ther., 2007, 9, R71.
68. Khalil, M.; Inaba, K.; Steinman, R.; Ravetch, J.; Diamond, B.T cell studies in a peptide-induced model of systemic lupus erythematosus. J. Immunol., 2001, 166, 1667-74.
69. Datta, S.K.; Mauri, C. Signalling defects and cellular interactions (2). Lupus, 2008, 17, 247-50.
70. Hom, G.; Graham, R.R.; Modrek, B.; Taylor, K.E.; Ortmann, W.; Garnier, S.; Lee, A.T.; Chung, S.A.; Ferreira, R.C.; Pant, P.V.; Ballinger, D.G.; Kosoy, R.; Demirci, F.Y.; Kamboh, M.I.; Kao, A.H.; Tian, C.; Gunnarsson, I.; Bengtsson, A.A.; Rantapaa-Dahlqvist, S.; Petri, M.; Manzi, S.; Seldin, M.F.; Ronnblom, L.; Syvanen, A.C.; Criswell, L.A.; Gregersen, P.K.; Behrens, T.W. Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX. N. Engl. J. Med., 2008, 358, 900-9.
71. Mendlovic, S.; Brocke, S.; Shoenfeld, Y.; Ben-Bassat, M.; Meshorer, A.; Bakimer, R.; Mozes, E. Induction of a systemic lupus erythematosus-like disease in mice by a common human anti-DNA idiotype. Proc. Natl. Acad. Sci. USA, 1988, 85, 2260-4.
72. Waisman, A.; Shoenfeld, Y.; Blank, M.; Ruiz, P.J.; Mozes, E. The pathogenic human monoclonal anti-DNA that induces experimental systemic lupus erythematosus in mice is encoded by a VH4 gene segment. Int. Immunol., 1995, 7, 689-96.
73. Luger, D.; Dayan, M.; Zinger, H.; Liu, J.P.; Mozes, E. A peptide based on the complementarity determining region 1 of a human monoclonal autoantibody ameliorates spontaneous and induced lupus manifestations in correlation with cytokine immunomodulation. J. Clin. Immunol., 2004, 24, 579-90.
74. Elmann, A.; Sharabi, A.; Dayan, M.; Zinger, H.; Ophir, R.; Mozes, E. Altered gene expression in mice with lupus treated with edratide, a peptide that ameliorates the disease manifestations. Arthritis Rheum., 2007, 56, 2371-81.
75. Monneaux, F.; Hoebeke, J.; Sordet, C.; Nonn, C.; Briand, J.P.; Maillere, B.; Sibillia, J.; Muller, S. Selective modulation of CD4+ T cells from lupus patients by a promiscuous, protective peptide analog. J. Immunol., 2005, 175, 5839-47.
76. Kalsi, J.K.; Grossman, J.; Kim, J.; Sieling, P.; Gjertson, D.W.; Reed, E.F.; Ebling, F.M.; Linker-Israeli, M.; Hahn, B.H. Peptides from antibodies to DNA elicit cytokine release from peripheral blood mononuclear cells of patients with systemic lupus erythematosus: relation of cytokine pattern to disease duration. Lupus, 2004, 13, 490-500.